nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ALK—lymphatic system cancer	0.876	1	CbGaD
Crizotinib—Neutrophil count decreased—Fludarabine—lymphatic system cancer	0.00476	0.0419	CcSEcCtD
Crizotinib—Lymphopenia—Mechlorethamine—lymphatic system cancer	0.00375	0.033	CcSEcCtD
Crizotinib—Disease progression—Carmustine—lymphatic system cancer	0.00364	0.0321	CcSEcCtD
Crizotinib—Periorbital oedema—Bleomycin—lymphatic system cancer	0.00231	0.0203	CcSEcCtD
Crizotinib—Haemoglobin decreased—Fludarabine—lymphatic system cancer	0.00181	0.0159	CcSEcCtD
Crizotinib—CYP3A5—Teniposide—lymphatic system cancer	0.00169	0.271	CbGbCtD
Crizotinib—Febrile neutropenia—Bleomycin—lymphatic system cancer	0.00152	0.0133	CcSEcCtD
Crizotinib—Sinus bradycardia—Mitoxantrone—lymphatic system cancer	0.00151	0.0133	CcSEcCtD
Crizotinib—PLK4—Etoposide—Teniposide—lymphatic system cancer	0.00143	0.337	CbGdCrCtD
Crizotinib—Neuropathy—Teniposide—lymphatic system cancer	0.00133	0.0117	CcSEcCtD
Crizotinib—Febrile neutropenia—Carmustine—lymphatic system cancer	0.00132	0.0116	CcSEcCtD
Crizotinib—Transaminases increased—Carmustine—lymphatic system cancer	0.00131	0.0115	CcSEcCtD
Crizotinib—Interstitial lung disease—Bleomycin—lymphatic system cancer	0.00129	0.0113	CcSEcCtD
Crizotinib—Respiratory failure—Fludarabine—lymphatic system cancer	0.00127	0.0111	CcSEcCtD
Crizotinib—Febrile neutropenia—Vincristine—lymphatic system cancer	0.00126	0.0111	CcSEcCtD
Crizotinib—Febrile neutropenia—Mitoxantrone—lymphatic system cancer	0.00123	0.0108	CcSEcCtD
Crizotinib—Sepsis—Teniposide—lymphatic system cancer	0.00123	0.0108	CcSEcCtD
Crizotinib—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.00117	0.0103	CcSEcCtD
Crizotinib—Burning sensation—Carmustine—lymphatic system cancer	0.00115	0.0101	CcSEcCtD
Crizotinib—Interstitial lung disease—Carmustine—lymphatic system cancer	0.00112	0.00989	CcSEcCtD
Crizotinib—AURKA—Etoposide—Teniposide—lymphatic system cancer	0.00112	0.264	CbGdCrCtD
Crizotinib—Haemoglobin decreased—Mitoxantrone—lymphatic system cancer	0.00107	0.00946	CcSEcCtD
Crizotinib—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.00105	0.00919	CcSEcCtD
Crizotinib—Hepatotoxicity—Carmustine—lymphatic system cancer	0.00103	0.00907	CcSEcCtD
Crizotinib—Abscess—Carmustine—lymphatic system cancer	0.00101	0.00885	CcSEcCtD
Crizotinib—Hepatic failure—Fludarabine—lymphatic system cancer	0.001	0.00883	CcSEcCtD
Crizotinib—Visual disturbance—Fludarabine—lymphatic system cancer	0.000952	0.00838	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.000899	0.00791	CcSEcCtD
Crizotinib—Neutropenia—Teniposide—lymphatic system cancer	0.00083	0.0073	CcSEcCtD
Crizotinib—Gait disturbance—Carmustine—lymphatic system cancer	0.000815	0.00717	CcSEcCtD
Crizotinib—CYP3A5—Vincristine—lymphatic system cancer	0.000811	0.131	CbGbCtD
Crizotinib—Pulmonary embolism—Carmustine—lymphatic system cancer	0.000796	0.007	CcSEcCtD
Crizotinib—Gait disturbance—Vincristine—lymphatic system cancer	0.000778	0.00685	CcSEcCtD
Crizotinib—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.000776	0.00682	CcSEcCtD
Crizotinib—Respiratory failure—Vincristine—lymphatic system cancer	0.000773	0.0068	CcSEcCtD
Crizotinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.000767	0.123	CbGbCtD
Crizotinib—Leukopenia—Mechlorethamine—lymphatic system cancer	0.000751	0.00661	CcSEcCtD
Crizotinib—Neuropathy—Carmustine—lymphatic system cancer	0.000747	0.00657	CcSEcCtD
Crizotinib—Neutropenia—Fludarabine—lymphatic system cancer	0.000729	0.00642	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.000725	0.00638	CcSEcCtD
Crizotinib—Neuropathy—Vincristine—lymphatic system cancer	0.000713	0.00627	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.000709	0.00624	CcSEcCtD
Crizotinib—Pneumonia—Fludarabine—lymphatic system cancer	0.000699	0.00615	CcSEcCtD
Crizotinib—Sepsis—Carmustine—lymphatic system cancer	0.00069	0.00607	CcSEcCtD
Crizotinib—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.000682	0.006	CcSEcCtD
Crizotinib—Infection—Mechlorethamine—lymphatic system cancer	0.00068	0.00598	CcSEcCtD
Crizotinib—CYP3A4—Cytarabine—lymphatic system cancer	0.000667	0.107	CbGbCtD
Crizotinib—Skin disorder—Mechlorethamine—lymphatic system cancer	0.000665	0.00585	CcSEcCtD
Crizotinib—CYP3A4—Teniposide—lymphatic system cancer	0.000657	0.106	CbGbCtD
Crizotinib—Sepsis—Mitoxantrone—lymphatic system cancer	0.000642	0.00565	CcSEcCtD
Crizotinib—Arrhythmia—Teniposide—lymphatic system cancer	0.000635	0.00558	CcSEcCtD
Crizotinib—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.000621	0.00546	CcSEcCtD
Crizotinib—Hepatic failure—Vincristine—lymphatic system cancer	0.000614	0.0054	CcSEcCtD
Crizotinib—Febrile neutropenia—Methotrexate—lymphatic system cancer	0.000613	0.00539	CcSEcCtD
Crizotinib—Visual impairment—Fludarabine—lymphatic system cancer	0.000602	0.00529	CcSEcCtD
Crizotinib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000595	0.00524	CcSEcCtD
Crizotinib—Diplopia—Carmustine—lymphatic system cancer	0.000578	0.00508	CcSEcCtD
Crizotinib—Anaemia—Teniposide—lymphatic system cancer	0.000572	0.00503	CcSEcCtD
Crizotinib—Arrhythmia—Fludarabine—lymphatic system cancer	0.000558	0.00491	CcSEcCtD
Crizotinib—Face oedema—Carmustine—lymphatic system cancer	0.000558	0.00491	CcSEcCtD
Crizotinib—Leukopenia—Teniposide—lymphatic system cancer	0.000554	0.00487	CcSEcCtD
Crizotinib—Malnutrition—Fludarabine—lymphatic system cancer	0.000543	0.00478	CcSEcCtD
Crizotinib—Burning sensation—Methotrexate—lymphatic system cancer	0.00053	0.00467	CcSEcCtD
Crizotinib—ABCB1—Vincristine—lymphatic system cancer	0.000528	0.085	CbGbCtD
Crizotinib—Hypokalaemia—Carmustine—lymphatic system cancer	0.000526	0.00462	CcSEcCtD
Crizotinib—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.000521	0.00458	CcSEcCtD
Crizotinib—Weight decreased—Bleomycin—lymphatic system cancer	0.000517	0.00455	CcSEcCtD
Crizotinib—Pneumonia—Bleomycin—lymphatic system cancer	0.000513	0.00451	CcSEcCtD
Crizotinib—Muscular weakness—Carmustine—lymphatic system cancer	0.000509	0.00448	CcSEcCtD
Crizotinib—Oedema—Teniposide—lymphatic system cancer	0.000505	0.00444	CcSEcCtD
Crizotinib—Anaemia—Fludarabine—lymphatic system cancer	0.000502	0.00442	CcSEcCtD
Crizotinib—Infection—Teniposide—lymphatic system cancer	0.000501	0.00441	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.000496	0.00437	CcSEcCtD
Crizotinib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000489	0.0043	CcSEcCtD
Crizotinib—Leukopenia—Fludarabine—lymphatic system cancer	0.000486	0.00428	CcSEcCtD
Crizotinib—Muscular weakness—Vincristine—lymphatic system cancer	0.000486	0.00428	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000484	0.00425	CcSEcCtD
Crizotinib—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.000477	0.0042	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000474	0.00417	CcSEcCtD
Crizotinib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000468	0.00412	CcSEcCtD
Crizotinib—Neutropenia—Carmustine—lymphatic system cancer	0.000467	0.00411	CcSEcCtD
Crizotinib—Abscess—Methotrexate—lymphatic system cancer	0.000466	0.0041	CcSEcCtD
Crizotinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00046	0.074	CbGbCtD
Crizotinib—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000455	0.00401	CcSEcCtD
Crizotinib—Dyspnoea—Teniposide—lymphatic system cancer	0.00045	0.00396	CcSEcCtD
Crizotinib—Pneumonia—Carmustine—lymphatic system cancer	0.000448	0.00394	CcSEcCtD
Crizotinib—Neutropenia—Vincristine—lymphatic system cancer	0.000446	0.00392	CcSEcCtD
Crizotinib—Oedema—Fludarabine—lymphatic system cancer	0.000444	0.0039	CcSEcCtD
Crizotinib—Infection—Fludarabine—lymphatic system cancer	0.000441	0.00388	CcSEcCtD
Crizotinib—Decreased appetite—Teniposide—lymphatic system cancer	0.000439	0.00386	CcSEcCtD
Crizotinib—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.000436	0.00384	CcSEcCtD
Crizotinib—Vomiting—Mechlorethamine—lymphatic system cancer	0.000435	0.00383	CcSEcCtD
Crizotinib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000435	0.00383	CcSEcCtD
Crizotinib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000434	0.00382	CcSEcCtD
Crizotinib—Rash—Mechlorethamine—lymphatic system cancer	0.000432	0.0038	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000431	0.00379	CcSEcCtD
Crizotinib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000431	0.00379	CcSEcCtD
Crizotinib—Weight decreased—Vincristine—lymphatic system cancer	0.000431	0.00379	CcSEcCtD
Crizotinib—Pneumonia—Vincristine—lymphatic system cancer	0.000427	0.00376	CcSEcCtD
Crizotinib—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00042	0.00369	CcSEcCtD
Crizotinib—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000416	0.00366	CcSEcCtD
Crizotinib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000416	0.00366	CcSEcCtD
Crizotinib—Nausea—Mechlorethamine—lymphatic system cancer	0.000407	0.00358	CcSEcCtD
Crizotinib—Body temperature increased—Teniposide—lymphatic system cancer	0.000399	0.00351	CcSEcCtD
Crizotinib—Paraesthesia—Fludarabine—lymphatic system cancer	0.000398	0.0035	CcSEcCtD
Crizotinib—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000398	0.0035	CcSEcCtD
Crizotinib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000395	0.00348	CcSEcCtD
Crizotinib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000394	0.00346	CcSEcCtD
Crizotinib—Dyspepsia—Fludarabine—lymphatic system cancer	0.00039	0.00343	CcSEcCtD
Crizotinib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000386	0.00339	CcSEcCtD
Crizotinib—AURKA—Cladribine—Fludarabine—lymphatic system cancer	0.000385	0.0907	CbGdCrCtD
Crizotinib—Visual impairment—Carmustine—lymphatic system cancer	0.000385	0.00339	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000383	0.00337	CcSEcCtD
Crizotinib—Fatigue—Fludarabine—lymphatic system cancer	0.000382	0.00336	CcSEcCtD
Crizotinib—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00038	0.00334	CcSEcCtD
Crizotinib—Constipation—Fludarabine—lymphatic system cancer	0.000379	0.00334	CcSEcCtD
Crizotinib—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000378	0.00333	CcSEcCtD
Crizotinib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000377	0.00331	CcSEcCtD
Crizotinib—Respiratory failure—Methotrexate—lymphatic system cancer	0.000375	0.0033	CcSEcCtD
Crizotinib—Urethral disorder—Vincristine—lymphatic system cancer	0.000374	0.00329	CcSEcCtD
Crizotinib—Eye disorder—Carmustine—lymphatic system cancer	0.000373	0.00329	CcSEcCtD
Crizotinib—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000369	0.00324	CcSEcCtD
Crizotinib—Anaemia—Bleomycin—lymphatic system cancer	0.000368	0.00324	CcSEcCtD
Crizotinib—Asthenia—Teniposide—lymphatic system cancer	0.000362	0.00319	CcSEcCtD
Crizotinib—Arrhythmia—Carmustine—lymphatic system cancer	0.000357	0.00314	CcSEcCtD
Crizotinib—Leukopenia—Bleomycin—lymphatic system cancer	0.000357	0.00314	CcSEcCtD
Crizotinib—AURKA—Clofarabine—Fludarabine—lymphatic system cancer	0.000356	0.0839	CbGdCrCtD
Crizotinib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000354	0.00311	CcSEcCtD
Crizotinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000351	0.00308	CcSEcCtD
Crizotinib—Malnutrition—Carmustine—lymphatic system cancer	0.000348	0.00306	CcSEcCtD
Crizotinib—Diarrhoea—Teniposide—lymphatic system cancer	0.000345	0.00304	CcSEcCtD
Crizotinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000344	0.00302	CcSEcCtD
Crizotinib—AURKA—Clofarabine—Cytarabine—lymphatic system cancer	0.000336	0.0792	CbGdCrCtD
Crizotinib—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000332	0.00292	CcSEcCtD
Crizotinib—Vision blurred—Carmustine—lymphatic system cancer	0.000328	0.00288	CcSEcCtD
Crizotinib—Oedema—Bleomycin—lymphatic system cancer	0.000325	0.00286	CcSEcCtD
Crizotinib—Infection—Bleomycin—lymphatic system cancer	0.000323	0.00284	CcSEcCtD
Crizotinib—Anaemia—Carmustine—lymphatic system cancer	0.000321	0.00283	CcSEcCtD
Crizotinib—Vomiting—Teniposide—lymphatic system cancer	0.000321	0.00282	CcSEcCtD
Crizotinib—Sepsis—Methotrexate—lymphatic system cancer	0.00032	0.00281	CcSEcCtD
Crizotinib—ABCB1—Methotrexate—lymphatic system cancer	0.00032	0.0514	CbGbCtD
Crizotinib—Asthenia—Fludarabine—lymphatic system cancer	0.000318	0.0028	CcSEcCtD
Crizotinib—Rash—Teniposide—lymphatic system cancer	0.000318	0.0028	CcSEcCtD
Crizotinib—Dermatitis—Teniposide—lymphatic system cancer	0.000318	0.0028	CcSEcCtD
Crizotinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000317	0.00279	CcSEcCtD
Crizotinib—CYP3A4—Vincristine—lymphatic system cancer	0.000316	0.0509	CbGbCtD
Crizotinib—AURKA—Gemcitabine—Cytarabine—lymphatic system cancer	0.000312	0.0734	CbGdCrCtD
Crizotinib—Leukopenia—Carmustine—lymphatic system cancer	0.000311	0.00274	CcSEcCtD
Crizotinib—Anaemia—Vincristine—lymphatic system cancer	0.000307	0.0027	CcSEcCtD
Crizotinib—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000305	0.00268	CcSEcCtD
Crizotinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000303	0.00267	CcSEcCtD
Crizotinib—AURKA—Cytarabine—Fludarabine—lymphatic system cancer	0.000303	0.0714	CbGdCrCtD
Crizotinib—Nausea—Teniposide—lymphatic system cancer	0.0003	0.00264	CcSEcCtD
Crizotinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000299	0.00263	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—lymphatic system cancer	0.000298	0.00262	CcSEcCtD
Crizotinib—Leukopenia—Vincristine—lymphatic system cancer	0.000297	0.00261	CcSEcCtD
Crizotinib—Paraesthesia—Bleomycin—lymphatic system cancer	0.000292	0.00257	CcSEcCtD
Crizotinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.00029	0.00255	CcSEcCtD
Crizotinib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000289	0.00255	CcSEcCtD
Crizotinib—Oedema—Carmustine—lymphatic system cancer	0.000284	0.0025	CcSEcCtD
Crizotinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000283	0.00249	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—lymphatic system cancer	0.000282	0.00248	CcSEcCtD
Crizotinib—Infection—Carmustine—lymphatic system cancer	0.000282	0.00248	CcSEcCtD
Crizotinib—Vomiting—Fludarabine—lymphatic system cancer	0.000282	0.00248	CcSEcCtD
Crizotinib—Rash—Fludarabine—lymphatic system cancer	0.00028	0.00246	CcSEcCtD
Crizotinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000279	0.00246	CcSEcCtD
Crizotinib—Oedema—Vincristine—lymphatic system cancer	0.000271	0.00238	CcSEcCtD
Crizotinib—Infection—Vincristine—lymphatic system cancer	0.000269	0.00237	CcSEcCtD
Crizotinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000266	0.00234	CcSEcCtD
Crizotinib—Oedema—Mitoxantrone—lymphatic system cancer	0.000264	0.00232	CcSEcCtD
Crizotinib—Nausea—Fludarabine—lymphatic system cancer	0.000263	0.00232	CcSEcCtD
Crizotinib—Infection—Mitoxantrone—lymphatic system cancer	0.000262	0.00231	CcSEcCtD
Crizotinib—Shock—Mitoxantrone—lymphatic system cancer	0.00026	0.00228	CcSEcCtD
Crizotinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000257	0.00226	CcSEcCtD
Crizotinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000256	0.00226	CcSEcCtD
Crizotinib—Paraesthesia—Carmustine—lymphatic system cancer	0.000255	0.00224	CcSEcCtD
Crizotinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000253	0.00223	CcSEcCtD
Crizotinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000247	0.00217	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000245	0.00216	CcSEcCtD
Crizotinib—Paraesthesia—Vincristine—lymphatic system cancer	0.000243	0.00214	CcSEcCtD
Crizotinib—Constipation—Carmustine—lymphatic system cancer	0.000243	0.00214	CcSEcCtD
Crizotinib—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000237	0.00208	CcSEcCtD
Crizotinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000236	0.00207	CcSEcCtD
Crizotinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000235	0.00207	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000234	0.00206	CcSEcCtD
Crizotinib—Fatigue—Vincristine—lymphatic system cancer	0.000234	0.00206	CcSEcCtD
Crizotinib—Asthenia—Bleomycin—lymphatic system cancer	0.000233	0.00205	CcSEcCtD
Crizotinib—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000232	0.00204	CcSEcCtD
Crizotinib—Constipation—Vincristine—lymphatic system cancer	0.000232	0.00204	CcSEcCtD
Crizotinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000229	0.00202	CcSEcCtD
Crizotinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000228	0.002	CcSEcCtD
Crizotinib—Constipation—Mitoxantrone—lymphatic system cancer	0.000226	0.00199	CcSEcCtD
Crizotinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000224	0.00197	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000216	0.0019	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000215	0.00189	CcSEcCtD
Crizotinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000214	0.00188	CcSEcCtD
Crizotinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000209	0.00184	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000207	0.00182	CcSEcCtD
Crizotinib—Vomiting—Bleomycin—lymphatic system cancer	0.000207	0.00182	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000206	0.00181	CcSEcCtD
Crizotinib—Infestation—Methotrexate—lymphatic system cancer	0.000206	0.00181	CcSEcCtD
Crizotinib—Rash—Bleomycin—lymphatic system cancer	0.000205	0.0018	CcSEcCtD
Crizotinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000205	0.0018	CcSEcCtD
Crizotinib—Asthenia—Carmustine—lymphatic system cancer	0.000204	0.00179	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000195	0.00172	CcSEcCtD
Crizotinib—Asthenia—Vincristine—lymphatic system cancer	0.000194	0.00171	CcSEcCtD
Crizotinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000194	0.00171	CcSEcCtD
Crizotinib—Nausea—Bleomycin—lymphatic system cancer	0.000193	0.0017	CcSEcCtD
Crizotinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000189	0.00167	CcSEcCtD
Crizotinib—Dizziness—Carmustine—lymphatic system cancer	0.000188	0.00165	CcSEcCtD
Crizotinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000185	0.00163	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000183	0.00161	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000181	0.0016	CcSEcCtD
Crizotinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000181	0.00159	CcSEcCtD
Crizotinib—Vomiting—Carmustine—lymphatic system cancer	0.00018	0.00159	CcSEcCtD
Crizotinib—Dizziness—Vincristine—lymphatic system cancer	0.000179	0.00158	CcSEcCtD
Crizotinib—Rash—Carmustine—lymphatic system cancer	0.000179	0.00157	CcSEcCtD
Crizotinib—Dermatitis—Carmustine—lymphatic system cancer	0.000179	0.00157	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—lymphatic system cancer	0.000178	0.00157	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—lymphatic system cancer	0.000173	0.00152	CcSEcCtD
Crizotinib—Vomiting—Vincristine—lymphatic system cancer	0.000172	0.00152	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000172	0.00151	CcSEcCtD
Crizotinib—Rash—Vincristine—lymphatic system cancer	0.000171	0.0015	CcSEcCtD
Crizotinib—Dermatitis—Vincristine—lymphatic system cancer	0.000171	0.0015	CcSEcCtD
Crizotinib—Nausea—Carmustine—lymphatic system cancer	0.000169	0.00148	CcSEcCtD
Crizotinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000168	0.00148	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000167	0.00147	CcSEcCtD
Crizotinib—Rash—Mitoxantrone—lymphatic system cancer	0.000166	0.00146	CcSEcCtD
Crizotinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000166	0.00146	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000161	0.00142	CcSEcCtD
Crizotinib—Nausea—Vincristine—lymphatic system cancer	0.000161	0.00142	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000158	0.00139	CcSEcCtD
Crizotinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000157	0.00138	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—lymphatic system cancer	0.000152	0.00134	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—lymphatic system cancer	0.000149	0.00131	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—lymphatic system cancer	0.000144	0.00127	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000136	0.0012	CcSEcCtD
Crizotinib—Infection—Methotrexate—lymphatic system cancer	0.000131	0.00115	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000129	0.00113	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—lymphatic system cancer	0.000128	0.00112	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—lymphatic system cancer	0.000118	0.00104	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—lymphatic system cancer	0.000117	0.00103	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—lymphatic system cancer	0.000116	0.00102	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—lymphatic system cancer	0.000114	0.00101	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000114	0.000999	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—lymphatic system cancer	0.000113	0.000997	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—lymphatic system cancer	0.000104	0.000914	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—lymphatic system cancer	9.43e-05	0.00083	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—lymphatic system cancer	9e-05	0.000791	CcSEcCtD
Crizotinib—Dizziness—Methotrexate—lymphatic system cancer	8.69e-05	0.000765	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—lymphatic system cancer	8.36e-05	0.000735	CcSEcCtD
Crizotinib—Rash—Methotrexate—lymphatic system cancer	8.29e-05	0.000729	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—lymphatic system cancer	8.28e-05	0.000729	CcSEcCtD
Crizotinib—Nausea—Methotrexate—lymphatic system cancer	7.81e-05	0.000687	CcSEcCtD
Crizotinib—CSF1R—Differentiation Pathway—ALK—lymphatic system cancer	5.08e-05	0.134	CbGpPWpGaD
Crizotinib—FES—IL4-mediated signaling events—BCL6—lymphatic system cancer	3.89e-05	0.103	CbGpPWpGaD
Crizotinib—AURKA—Aurora B signaling—NPM1—lymphatic system cancer	2.83e-05	0.0748	CbGpPWpGaD
Crizotinib—CDK7—Negative epigenetic regulation of rRNA expression—RRP8—lymphatic system cancer	2.57e-05	0.0679	CbGpPWpGaD
Crizotinib—JAK3—IL4-mediated signaling events—BCL6—lymphatic system cancer	2.54e-05	0.0671	CbGpPWpGaD
Crizotinib—MET—Direct p53 effectors—BCL6—lymphatic system cancer	2.32e-05	0.0612	CbGpPWpGaD
Crizotinib—CDK7—Epigenetic regulation of gene expression—RRP8—lymphatic system cancer	2.28e-05	0.0602	CbGpPWpGaD
Crizotinib—MAP4K1—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	2.19e-05	0.0578	CbGpPWpGaD
Crizotinib—RPS6KB1—IL4-mediated signaling events—BCL6—lymphatic system cancer	2.07e-05	0.0547	CbGpPWpGaD
Crizotinib—BLK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	1.52e-05	0.0402	CbGpPWpGaD
Crizotinib—EPHA2—Direct p53 effectors—BCL6—lymphatic system cancer	1.5e-05	0.0394	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—PROX1—lymphatic system cancer	1.38e-05	0.0363	CbGpPWpGaD
Crizotinib—JAK2—IL4-mediated signaling events—BCL6—lymphatic system cancer	1.22e-05	0.0323	CbGpPWpGaD
Crizotinib—LYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	9.15e-06	0.0241	CbGpPWpGaD
Crizotinib—ABL1—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	8.29e-06	0.0219	CbGpPWpGaD
Crizotinib—LCK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	7.5e-06	0.0198	CbGpPWpGaD
Crizotinib—NEK9—Cell Cycle—NPM1—lymphatic system cancer	7.15e-06	0.0189	CbGpPWpGaD
Crizotinib—CDK7—HIV Infection—NPM1—lymphatic system cancer	5.54e-06	0.0146	CbGpPWpGaD
Crizotinib—LCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	3.85e-06	0.0101	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—RRP8—lymphatic system cancer	3.81e-06	0.0101	CbGpPWpGaD
Crizotinib—AURKA—Cell Cycle—NPM1—lymphatic system cancer	3.58e-06	0.00945	CbGpPWpGaD
Crizotinib—PLK4—Cell Cycle—NPM1—lymphatic system cancer	3.43e-06	0.00906	CbGpPWpGaD
Crizotinib—ABCB1—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	3.38e-06	0.00892	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—NPM1—lymphatic system cancer	2.65e-06	0.00698	CbGpPWpGaD
Crizotinib—LCK—HIV Infection—NPM1—lymphatic system cancer	2.5e-06	0.00659	CbGpPWpGaD
Crizotinib—CDK7—Disease—NPM1—lymphatic system cancer	1.36e-06	0.00358	CbGpPWpGaD
Crizotinib—TYK2—Disease—NPM1—lymphatic system cancer	9.23e-07	0.00243	CbGpPWpGaD
Crizotinib—JAK2—Disease—NPM1—lymphatic system cancer	6.99e-07	0.00184	CbGpPWpGaD
Crizotinib—LCK—Disease—NPM1—lymphatic system cancer	6.12e-07	0.00162	CbGpPWpGaD
Crizotinib—SRC—Disease—NPM1—lymphatic system cancer	5.42e-07	0.00143	CbGpPWpGaD
